Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunological monitoring substudy of first-line bosutinib or imatinib in chronic phase chronic myeloid leukemia
NL-OMON42791Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of bosutinib and imatinib in chronic myelogenous leukemia (CML) (2 cohorts), sponsored by Vrije University Medical Center. Primary endpoint: Immunological changes induced by bosutinib and/or imatinib. Started Jul 2015; status: active, not recruiting.
02
Drugs
bosutinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON42791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42791.